Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $56.36.

A number of research firms have recently weighed in on KYMR. BMO Capital Markets assumed coverage on Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Citigroup started coverage on Kymera Therapeutics in a research note on Thursday. They issued a “buy” rating and a $52.00 price target for the company. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, HC Wainwright increased their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, February 28th.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock valued at $455,202 in the last three months. 15.82% of the stock is currently owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently modified their holdings of the business. Blue Trust Inc. raised its position in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the period. State of Wyoming purchased a new position in Kymera Therapeutics during the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at about $55,000. KBC Group NV lifted its position in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Kymera Therapeutics during the third quarter worth approximately $95,000.

Kymera Therapeutics Stock Performance

KYMR stock opened at $33.45 on Friday. Kymera Therapeutics has a 1 year low of $29.07 and a 1 year high of $53.27. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -14.29 and a beta of 2.22. The stock’s fifty day moving average is $37.57 and its two-hundred day moving average is $42.95.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. As a group, analysts predict that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.